Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 26;13(11):2617.
doi: 10.3390/cancers13112617.

Optimizing Loco Regional Management of Oligometastatic Colorectal Cancer: Technical Aspects and Biomarkers, Two Sides of the Same Coin

Giovanni Mauri  1   2 , Lorenzo Monfardini  3 , Andrea Garnero  4   5 , Maria Giulia Zampino  6 , Franco Orsi  1 , Paolo Della Vigna  1 , Guido Bonomo  1 , Gianluca Maria Varano  1 , Marco Busso  4 , Carlo Gazzera  7 , Paolo Fonio  5   7 , Andrea Veltri  4   8 , Marco Calandri  4   8
Affiliations
Review

Optimizing Loco Regional Management of Oligometastatic Colorectal Cancer: Technical Aspects and Biomarkers, Two Sides of the Same Coin

Giovanni Mauri et al. Cancers (Basel). .

Abstract

Colorectal cancer (CRC) is the third most common cancer worldwide and has a high rate of metastatic disease which is the main cause of CRC-related death. Oligometastatic disease is a clinical condition recently included in ESMO guidelines that can benefit from a more aggressive locoregional approach. This review focuses the attention on colorectal liver metastases (CRLM) and highlights recommendations and therapeutic locoregional strategies drawn from the current literature and consensus conferences. The different percutaneous therapies (radiofrequency ablation, microwave ablation, irreversible electroporation) as well as trans-arterial approaches (chemoembolization and radioembolization) are discussed. Ablation margins, the choice of the imaging guidance as well as characteristics of the different ablation techniques and other technical aspects are analyzed. A specific attention is then paid to the increasing role of biomarkers (in particular molecular profiling) and their role in the selection of the proper treatment for the right patient. In conclusion, in this review an up-to-date state of the art of the application of locoregional treatments on CRLM is provided, highlighting both technical aspects and the role of biomarkers, two sides of the same coin.

Keywords: chemotherapy; colorectal cancer; loco regional treatments; oligometastatic disease; surgery.

PubMed Disclaimer

Conflict of interest statement

G.M. received speaking fee from GE (General Electric). All other authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Miller K.D., Siegel R.L., Khan R., Jemal A. Cancer Statistics. Cancer Rehabil. 2018;70:7–30. doi: 10.1891/9780826121646.0002. - DOI - PubMed
    1. Cunningham D., Atkin W., Lenz H.-J., Lynch H.T., Minsky B., Nordlinger B., Starling N. Colorectal cancer. Lancet Lond. Engl. 2010;375:1030–1047. doi: 10.1016/S0140-6736(10)60353-4. - DOI - PubMed
    1. Fidler M.M., Soerjomataram I., Bray F. A global view on cancer incidence and national levels of the human development index. Int. J. Cancer. 2016;139:2436–2446. doi: 10.1002/ijc.30382. - DOI - PubMed
    1. Hellman S., Weichselbaum R.R. Oligometastases. J. Clin. Oncol. 1995;13:8–10. doi: 10.1200/JCO.1995.13.1.8. - DOI - PubMed
    1. Wild A.T., Yamada Y. Treatment Options in Oligometastatic Disease: Stereotactic Body Radiation Therapy–Focus on Colorectal Cancer. Visc. Med. 2017;33:54–61. doi: 10.1159/000454685. - DOI - PMC - PubMed